JP2022523680A5 - - Google Patents

Info

Publication number
JP2022523680A5
JP2022523680A5 JP2021543207A JP2021543207A JP2022523680A5 JP 2022523680 A5 JP2022523680 A5 JP 2022523680A5 JP 2021543207 A JP2021543207 A JP 2021543207A JP 2021543207 A JP2021543207 A JP 2021543207A JP 2022523680 A5 JP2022523680 A5 JP 2022523680A5
Authority
JP
Japan
Prior art keywords
cells
pharmaceutical composition
composition according
once
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021543207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523680A (ja
JP7675014B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014836 external-priority patent/WO2020154534A1/en
Publication of JP2022523680A publication Critical patent/JP2022523680A/ja
Publication of JP2022523680A5 publication Critical patent/JP2022523680A5/ja
Priority to JP2025072923A priority Critical patent/JP2025118706A/ja
Application granted granted Critical
Publication of JP7675014B2 publication Critical patent/JP7675014B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021543207A 2019-01-23 2020-01-23 Ｂ細胞免疫療法 Active JP7675014B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025072923A JP2025118706A (ja) 2019-01-23 2025-04-25 Ｂ細胞免疫療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962795629P 2019-01-23 2019-01-23
US62/795,629 2019-01-23
US201962837765P 2019-04-24 2019-04-24
US62/837,765 2019-04-24
US202062965032P 2020-01-23 2020-01-23
PCT/US2020/014836 WO2020154534A1 (en) 2019-01-23 2020-01-23 B cell immunotherapy
US62/965,032 2020-01-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025072923A Division JP2025118706A (ja) 2019-01-23 2025-04-25 Ｂ細胞免疫療法

Publications (3)

Publication Number Publication Date
JP2022523680A JP2022523680A (ja) 2022-04-26
JP2022523680A5 true JP2022523680A5 (https=) 2023-02-01
JP7675014B2 JP7675014B2 (ja) 2025-05-12

Family

ID=71735798

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543207A Active JP7675014B2 (ja) 2019-01-23 2020-01-23 Ｂ細胞免疫療法
JP2025072923A Pending JP2025118706A (ja) 2019-01-23 2025-04-25 Ｂ細胞免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025072923A Pending JP2025118706A (ja) 2019-01-23 2025-04-25 Ｂ細胞免疫療法

Country Status (4)

Country Link
US (1) US20220079986A1 (https=)
JP (2) JP7675014B2 (https=)
CA (1) CA3127623A1 (https=)
WO (1) WO2020154534A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022094284A1 (en) * 2020-10-30 2022-05-05 Immusoft Corporation Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents
US20250012798A1 (en) * 2021-11-11 2025-01-09 The General Hospital Corporation Methods for defining stages and progression of amyotrophic lateral sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555457C (en) 2004-02-09 2012-08-21 Mitsubishi Pharma Corporation A novel therapeutic agent for amyotrophic lateral sclerosis (als) or diseases caused by als
WO2006119170A2 (en) 2005-05-02 2006-11-09 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
US9669057B2 (en) 2008-04-25 2017-06-06 Duke University Regulatory B cells and their uses
EP2576772B1 (en) * 2010-05-26 2018-12-12 Deutsches Rheuma-Forschungszentrum Berlin Antigen-presenting modified naïve b cells for immune suppression and a method for producing said modified cells
WO2012136587A1 (en) * 2011-04-04 2012-10-11 HumaCell Inc. Repair of neurodegenerative disease
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease

Similar Documents

Publication Publication Date Title
Hendrix et al. The role of T helper cells in neuroprotection and regeneration
US5709853A (en) Method of treatment of atopic disease
Liu et al. The roles of Th cells in myocardial infarction
Ahuja et al. Comparative evaluation of effectiveness of autologous platelet rich plasma and intralesional corticosteroids in the management of erosive oral Lichen planus-a clinical study
Tano et al. A daily nasal spray with saline prevents symptoms of rhinitis
JP2025118706A5 (https=)
JP2022523680A5 (https=)
Pasquier et al. “Hemicrania continua”: The first bilateral case?
Kanda et al. Interferon-lnduced Sudden Hearing Loss
WO2021206459A1 (ko) 통증조절인자를 함유한 줄기세포유래 엑소좀 및 그 용도
Schwartz et al. The vicious cycle governing the brain–immune system relationship in neurodegenerative diseases
Gholizadeh et al. Intralesional corticosteroid injection as an effective treatment method for oral lesions: a meta-analysis
Goulden et al. Recombinant granulocyte colony‐stimulating factor in the management of toxic epidermal necrolysis
Harvey et al. Chlormethiazole in treatment of status epilepticus.
Kander et al. Acute epiglottitis in adults
Spink et al. Persistent menace of pneumococcal meningitis
Kawai et al. On the conservative treatment of Bell's palsy
JP2021520353A5 (https=)
CN114288314A (zh) 克拉屈滨在制备用于预防或治疗银屑病药物中的用途
Yang et al. Interferon-alpha in the management of patients with Behcet's disease
Kang et al. Mucosal deposit after triamcinolone injection: a case report
US20250002559A1 (en) Pharmaceutical formulation for treatment of cerebral stroke
DE69618511T2 (de) Gammainterferon enthaltende Zusammensetzung zur Prurigo-Behandlung
JPH10273448A (ja) アトピー性疾患治療のための口腔内投与用治療薬
RU2304971C2 (ru) Способ лечения рецидивирующего герпетического стоматита, осложненного соматоформным болевым расстройством